Sharon Tetlow

Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP

Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA.

Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA.